Phase 2B COPD Trial to Use Point-of-Care Test for Rhinovirus Detection
The phase 2B trial of vapendavir will use bioMérieux’s Biofire Spotfire panel—a CLIA-waived molecular test that detects rhinovirus—to confirm infections in COPD patients.
The phase 2B trial of vapendavir will use bioMérieux’s Biofire Spotfire panel—a CLIA-waived molecular test that detects rhinovirus—to confirm infections in COPD patients.
Researchers developed a portable, at-home, wireless device that simultaneously detects SARS-CoV-2 and vitamin C levels.
Labcorp introduced a molecular H5 bird flu test to help diagnose human infections with the H5N1 virus, enhancing public health response.
An international team thinks they have the solution to identify infection in a wound: a device run from a smartphone or tablet app.
The FDA has authorized Cepheid's Xpert HCV test and GeneXpert Xpress System, the first point-of-care HCV test for certified settings.
Sekisui formalized an exclusive distribution agreement with Aptitude Medical Systems to sell the Aptitude Metrix COVID Test in the U.S.Â